- $4.00bn
- $4.00bn
- $3.10bn
Annual income statement for Minimed, fiscal year end - April 24th, USD millions except per share, conversion factor applied.
2023 April 28th | 2024 April 26th | 2026 April 24th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | USG | USG | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 2,245 | 2,469 | 3,102 |
| Cost of Revenue | |||
| Gross Profit | 1,308 | 1,437 | 1,680 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 2,314 | 2,538 | 3,290 |
| Operating Profit | -69 | -69 | -188 |
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -76 | -70 | -187 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -92 | -108 | -315 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -97 | -113 | -331 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -96 | -112 | -331 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.219 | -0.327 | -1.25 |